Skip to content
Posttest/Evaluation: A Wake-Up Call: Improving Recognition and Management of Excessive Daytime Sleepiness in Patients with Obstructive Sleep Apnea – Livestream #2 (ID: i809-2)
In order to receive a CME certificate for your participation in this activity, please complete this form in its entirety.
*
1.
To receive CME credit for completing this activity, please provide your full name, degree/specialty, and email address.
(Required.)
Name
Degree & Specialty
State/Province
Email Address
*
2.
Request for Credit
(Required.)
I participated in the entire activity and claim 0.75 credit.
I participated in only part of the activity and claim 0.50 credit.
I participated in only part of the activity and claim 0.25 credit.
*
3.
After participating in this activity, how confident are you in the management of excessive daytime sleepiness in patients with obstructive sleep apnea in your practice?
(Required.)
Very confident
Confident
Neutral
Little confidence
No confidence
*
4.
How many years have you been in practice?
(Required.)
≥21
11-20
1-10
<1
*
5.
How many patients with OSA do you manage per week?
(Required.)
1 to 10
11 to 25
26 to 50
I am not directly involved in patient care
*
6.
Please select the option that best describes your practice setting:
(Required.)
Academic medical center
Community hospital or medical center
VA, DOD or other government
Managed Care
Research
Pharmaceutical industry
*
7.
Dominic is 58-year-old man who presents with EDS despite optimal adherence to CPAP therapy. While discussing his treatment options, he conveys that he would prefer a medication that has been shown to last at least 9–10 hours (the duration of his typical workday). Based on this information, which is the best choice of therapy for Dominic?
(Required.)
Modafinil
Methylphenidate
Solriamfetol
8.
Which of these is a key topic for patient education to ensure optimal outcomes in the management of EDS?
The importance of good sleep hygiene
The need to document sleep patterns to assess treatment response
The use of objective measures of sleepiness
*
9.
How committed are you to making changes in your practice based on your participation in this activity?
(Required.)
Very committed
Committed
Neutral
Not committed
I do not plan to make changes
If not committed or do not plan to make changes, please indicate reason
*
10.
Which of the following best describes the impact of this activity on your performance?
(Required.)
I gained new strategies/skills/information I can apply to my area of practice
I need more information before I can change my practice
My practice is already consistent with the information presented
This activity will not change my practice
*
11.
Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.
(Required.)
Better understanding of recent data on FDA-approved and emerging therapies for patients with EDS, including their impact on daily function and QOL
Ability to safely incorporate FDA-approved and emerging therapies
Improve health outcomes among diverse patients with EDS
Address AEs and improve QOL in patients with EDS
*
12.
What barriers do you see to making changes in your practice? Please select all that apply.
(Required.)
Lack of knowledge regarding evidence-based strategies
Lack of convincing evidence to warrant change
Lack of time/resources to consider change
Insurance, reimbursement or legal issues
Conflicting guidelines or evidence
Patient compliance and/or patient resource barriers
Other (please explain)
*
13.
Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree
After participating in today’s activity, I am now better able to:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
SUMMARIZE available treatments for EDS in OSA, including their impact on daily function and quality of life
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
INTEGRATE patient education strategies when prescribing wake-promoting agents to optimized patient outcomes and adherence
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
*
14.
Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree
Seema Khosla, MD, FCCP, FAASM effectively:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Presented the Material
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Avoided Commercial Bias
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
*
15.
Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree
Andrea Matsumura, MD, MS effectively:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Presented the Material
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Avoided Commercial Bias
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
*
16.
Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree
Michael Thorpy, MD effectively:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Presented the Material
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Avoided Commercial Bias
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
*
17.
Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree
The content presented:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Enhanced my current knowledge base
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Addressed my most pressing questions
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Promoted improvements or quality in health care
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Was scientifically rigorous and evidence based
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Avoided commercial bias or influence
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
18.
If you indicated that you perceived commercial bias or influence, please describe:
19.
As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?
20.
Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or a related disease state: